Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (141-150 of 223) with videos related to

Pageof 23
Sort By:
Frontiers in Oncology|April 3, 2024
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutationsJiaqi Li, Mengqing Xie, Ruiying Zhao, et al.
Annals of Translational Medicine|February 8, 2021
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastasesMeng Qiao, Fei Zhou, Likun Hou, et al.
Oncotarget|December 3, 2016
Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinomaQi Wang, Ningning Cheng, Xuefei Li, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2021
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective studyXiangling Chu, Huiping Qiang, Mengqing Xie, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2021
Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020) 76-82]Xiangling Chu, Jing Zhao, Juan Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2019
Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing miceYijun Jia, Sha Zhao, Tao Jiang, et al.
Clinical Lung Cancer|July 21, 2018
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung CancerFengying Wu, Shijia Zhang, Anwen Xiong, et al.
International Journal of Molecular Sciences|October 27, 2022
A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung AdenocarcinomaBo Tang, Lanlin Hu, Tao Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2020
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsXiangling Chu, Jing Zhao, Juan Zhou, et al.
Journal of Thoracic Disease|September 4, 2018
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupTao Jiang, Chunxia Su, Shengxiang Ren, et al.
Pageof 23

Showing results (141-150 of 223) with videos related to

Sort By:
Pageof 23
Frontiers in Oncology|April 3, 2024
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutationsJiaqi Li, Mengqing Xie, Ruiying Zhao, et al.
Annals of Translational Medicine|February 8, 2021
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastasesMeng Qiao, Fei Zhou, Likun Hou, et al.
Oncotarget|December 3, 2016
Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinomaQi Wang, Ningning Cheng, Xuefei Li, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2021
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective studyXiangling Chu, Huiping Qiang, Mengqing Xie, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2021
Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020) 76-82]Xiangling Chu, Jing Zhao, Juan Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2019
Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing miceYijun Jia, Sha Zhao, Tao Jiang, et al.
Clinical Lung Cancer|July 21, 2018
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung CancerFengying Wu, Shijia Zhang, Anwen Xiong, et al.
International Journal of Molecular Sciences|October 27, 2022
A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung AdenocarcinomaBo Tang, Lanlin Hu, Tao Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2020
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsXiangling Chu, Jing Zhao, Juan Zhou, et al.
Journal of Thoracic Disease|September 4, 2018
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupTao Jiang, Chunxia Su, Shengxiang Ren, et al.
Pageof 23